Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
KIR2DS4 Antibody
NCTP09375
Description: Rabbit polyclonal to human KIR2DS4
Application: ELISA, WB, IHC
Reactivity: Human
Catalog #: NCTP09375
$380.00
1000 Items
Overview
| DESCRIPTION | |
| Species Reactivity | Human. Predicted: Rat, Mouse. |
| Isotype | IgG |
| Immunogen | Recombinant fragment corresponding to 46-217aa of human KIR2DS4. |
| Accession # | P43632 |
| Alternative Names | CD158I; KIR-2DS4; KIR1D; KIR2DS1; KIR412; KKA3; NKAT-8; NKAT8; Killer cell immunoglobulin-like receptor 2DS4 |
| Purification | Purified by antigen affinity column. |
| Formulation | Lyophilized power with 2% BSA and 0.02% NaN3 |
| Size | 100µg/200µl |
| APPLICATION | |
| ELISA | 1:10,000 – 1:100,000 |
| Western Blot | 1:200 – 1:2,000 |
| Immunohistochemistry | 1:100 - 1:500 |
| - | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
| PREPARATION AND STORAGE | |
| Reconstitution | Reconstitute in 200µl of sterile H2O. |
| Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
| REFERENCES | |
| - | Majorczyk E, Pawlik A, Gendosz D et al. Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment. BMC Musculoskelet Disord 15, 256 (2014). |